# A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

> **NCT06336291** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Philogen S.p.A.** · enrollment: 90 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** L19TNF
- **DRUG:** L19TNF
- **DRUG:** L19TNF
- **DRUG:** Lomustine
- **DRUG:** Lomustine

## Key facts

- **NCT ID:** NCT06336291
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-22
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06336291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06336291, "A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06336291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*